Headline Roundup • December 2nd, 2025
UK Agrees to Pay More for American Pharma, Secures Tariff Exemption on Own Drug Exports
Summary from the AllSides News Team
The US and UK reached a deal in which the UK agreed to pay about 25% more for US pharmaceuticals in return for a three-year tariff exemption on its pharmaceutical exports to the US.
The Details: UK pharmaceutical companies also agreed to continued investment in American drug development and manufacturing. The price increase marks the first time in 20 years that Britain's National Health Service (NHS) will spend more on medicine, as its expenditures had declined over that period.
For Context: President Trump and other administration officials have previously complained that some wealthy countries pay too little for medicine, forcing the costs onto the US. The New York Times (Lean Left bias) wrote, "American consumers ultimately bear some of those costs when they pay health insurance premiums and taxes." Trump had previously threatened a 100% tariff on the UK. Earlier this year, the US struck a significant trade deal with the European Union in which tariffs on pharmaceutical exports to the US would be capped at 15%.
Key Quotes: Both governments framed the deal as a win. UK Business and Trade Secretary Peter Kyle said, "This deal guarantees that UK pharmaceutical exports – worth at least £5 billion a year – will enter the US tariff-free, protecting jobs, boosting investment and paving the way for the UK to become a global hub for life sciences." US Secretary of Commerce Howard Lutnick said, "Today's agreement is a major win for American workers and our innovation economy. We are strengthening supply chains, creating high-quality jobs, and reinforcing America as the world's premier hub for life-sciences investment."
How The Media Covered It: The story was not widely covered by American outlets on the right, though many republished coverage from wire services like Reuters (Center) and Associated Press (Left). Britain's The Daily Mail (Lean Right) emphasized the cost to British taxpayers, which it states to be around £3 billion.
Written by the AllSides staff (of humans). Learn more. Support our mission.
Featured Coverage of this Story
onathan Nackstrand/Agence France-Presse — Getty Images
The United States and Britain announced a deal on Monday in which Britain would avoid potential tariffs on drug exports by agreeing to spend more on certain medicines covered through its national health service.
In Britain, a public body uses a complex formula to determine whether and how much the government will pay for new drugs, part of a process that results in lower drug prices there compared with the United States.
The UK and the US have agreed a deal to keep tariffs on UK pharmaceutical shipments into America at zero.
Under the agreement the UK will pay more for medicines through the NHS in return for a guarantee that US import taxes on pharmaceuticals made in the UK will remain at zero for three years.
This is the first time the amount that the NHS pays for medicines is due to increase in more than 20 years.
The United Kingdom will pay 25% more for new medications as part of a deal to avoid U.S. tariffs on Britain's drug exports to the U.S., a key step in President Donald Trump's push to get other nations to pay more for pharmaceuticals that he says U.S. consumers unfairly subsidize.
The deal also includes continued investment by U.K. pharmaceutical companies in the U.S., which U.S. officials said would strengthen American pharmaceutical development and manufacturing.
AllSides Picks
.jpg)
.png)
